
January 12th, 2022 – Epics Therapeutics S.A., a private drug development company, announced today the initiation of a First-in-Human, double-blind, placebo-controlled, single and multiple ascending dose study of EP282 to evaluate oral pharmacokinetics, pharmacodynamics, safety and tolerability in healthy male volunteers. Specific biomarkers will also be monitored to evaluate drug-target engagement at different dose levels. Successful completion of this Phase I study will enable the initiation of Proof-of-Concept Phase II studies of EP282 in patient suffering from gastrointestinal inflammatory disorders as well as establish dose levels for initial clinical evaluation for specific types of cancer. Phase II studies are projected to start mid-2023.

EP282 is a proprietary, oral, small molecule FFAR2 agonist discovered and developed at Epics Therapeutics. “We are the first company to bring an FFAR2 agonist into clinical development. FFAR2 is the focus of numerous published reports from the research community as it is an exciting target linking the microbiome with defence against intestinal infection, inflammation and cancer remission. Our preclinical dataset, in agreement with the published reports, indicates that our drug candidate represents a safe and powerful new approach for addressing the unmet medical needs in the treatment of gastrointestinal disorders and certain cancers” stated Jean Combalbert, CEO.

About Epics Therapeutics

Epics Therapeutics is a Belgian, private, drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic and G-Protein Coupled Receptor mechanisms involved in cancer development. By targeting these mechanisms, Epics Therapeutics aims to translate science into life-changing therapies for patients. www.epicstherapeutics.com